

PRESS RELEASE

Issued 07 April 2011

MULTI-MILLION BIOTECHNOLOGY LICENCE DEAL

Scanbio, a Norwegian fish by-products group and GlycoMar, a Scottish marine biotechnology company, are pleased to announce the signing of a collaboration and licence agreement to commercialise a nutritional supplement product worth up to £4m a year in gross sales. Scanbio Scotland, based in Corpach, Fort William have led the negotiation of the deal with Oban based bio-research specialists GlycoMar. The deal follows four years of research at GlycoMar's labs and small-scale trials at Scanbio's factories in Norway to produce an anti-inflammatory joint therapy product.

The deal provides the terms for licensing the technology from GlycoMar, in return for a future royalty on sales, and for the required collaboration to complete the commercialisation of the product. The licence gives Scanbio exclusive rights to use GlycoMar's proprietary extraction and purification technology to produce a natural anti-inflammatory nutritional supplement, aimed in this case at easing joint pain and inflammation. The financial terms of the deal are undisclosed. Chris Jones of Scanbio and GlycoMar's Dr Charlie Bavington met at a marine biotechnology day held in Inverness in 2007 and immediately saw that GlycoMar's discovery was something that Scanbio had exactly the right ingredients to put into production, leading to last weeks' tie-up.

Scanbio group specialise in processing fish by-products for the manufacture of a range of animal and fish feed ingredients. This deal is an important development for Scanbio which will see them adding new products much higher up the value chain. The process developed by GlycoMar will integrate fully with their current fish by-product processing and will provide a unique, natural, sustainable and traceable nutritional supplement product which out-performs those currently on the market.

Scanbio have a two year plan ahead of them to bring the project to fruition, by which time the as-yet un-branded new product will have been introduced to the international nutraceutical market place. "Made from the by-products from salmon processing, it will be the first product of its kind in the world to be made from a marine source" according to Chris Jones of Scanbio Scotland.

GlycoMar Limited, based at the European Centre for Marine Biotechnology, near Oban is a specialist biotechnology company discovering and developing new therapeutic products from marine resources. The company is developing anti-inflammatory products with applications in nutrition, cosmetics, and pharmaceuticals. GlycoMar's founder, Dr Charlie Bavington, said "we are very excited about this agreement, which is our first out-licensing deal in the nutritional sector. This is the outcome of several years research in utilisation of fisheries by-products. We are particularly delighted to be collaborating with Scanbio, who we believe are the best partner to commercialise this technology."

Ends

Notes to newsdesks:

For further information on Scanbio visit www.scanbio.co.uk

For further information on GlycoMar visit www.glycomar.com

For further information contact:

Chris Jones

T: 01397 773041

E: chris@scanbio.co.uk